Antibody Clinical Development Pharma Companies Regulation 
pharmaphorum
MARCH 9, 2021
Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Ablynx, which is now a subsidiary of Sanofi following a $4.8
pharmaphorum
DECEMBER 21, 2021
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 19, 2021
The French pharma just signed a deal with C4XD to develop drugs that could lead to oral medicines for inflammatory diseases such as psoriasis, as big pharma looks for more patient-friendly alternatives to therapies based on injections of antibody-based drugs. It spotlighted the UK as a place to do clinical development.
Roots Analysis
MAY 21, 2024
These are the vital structural component of cells, which help in cell functioning and regulation of building body tissues. However, continuous regulation of the cellular proteome is essential for maintaining the right balance of different proteins necessary for normal cellular function, survival, and proliferation.
pharmaphorum
APRIL 7, 2021
While the Darzalex revenues are due to fall this year because of Janssen’s interpretation of the agreement between the two companies, there are also other revenue streams. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.
The Pharma Data
DECEMBER 16, 2020
the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions.
pharmaphorum
APRIL 28, 2022
Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.
Expert insights. Personalized for you.
98 
Let's personalize your content